.
Bioiberica S.A.U.
A world reference in animal-derived APIs
Bioiberica is a global Life Science company specialised in the identification, extraction and development of biomolecules of high biological and therapeutic value for the pharmaceutical and nutraceutical industries. This specialisation has positioned Bioiberica among the leading Heparin API manufacturers and as a world reference in the research, production and sale of other animal-derived APIS and ingredients. These include:
Heparin – the most used clinical antithrombotic drug globally, which now saves more than 100 million lives the world over every year.
Thyroid API – Bioiberica’s Natural Desiccated Thyroid (NDT), extracted from porcine, contains tetraiodothyronine (thyroxine, T4) and triiodothyronine (liothyronine, T3), which are two different hormones naturally produced by the thyroid gland. Thyroid API from Bioiberica is entirely of European animal origin, compliant with US Pharmacopoeia and GMP-certified.
Chondroitin sulphate – a specific glycosaminoglycan used for the symptomatic treatment of osteoarthritis. It’s currently recommended by national and international therapeutic guidelines, with clinical trials demonstrating its effectiveness in reducing joint pain and increasing mobility.[i],[ii] Bioiberica’s chondroitin sulphate is the chemical reference substance in EU and US pharmacopoeias and obtained from various animal sources.
Glucosamine – an amino sugar precursor of glycosaminoglycans, used for the symptomatic treatment of mild knee osteoarthritis. Clinical trials demonstrate its ability to reduce joint pain and improve mobility[iii]. Glucosamine supplied by Bioiberica is produced by hydrolysis of crustacean shells and is available for sale in the form of any of its salts.
The partner of choice
Aside from its specialisation in substances of animal origin, Bioiberica’s production capacity, supply chain model and vertical integration guarantee full traceability, security and sustainability making it a trusted partner with which to grow and innovate.
In addition, the company’s commitment to international standards and industrial excellence means it delivers API quality, safety and regulatory compliance too.
Your active ingredient for innovation
Bioiberica is more than just a supplier – seeking partnership opportunities to support future innovation, by providing the scientific, regulatory, industrial and market expertise.
With the creation of tailor-made products, pilot manufacturing, scaling services, development of analytical methods to characterise complex molecules and regulatory expertise, Bioiberica is committed to supporting its partners’ business development.
To support future innovation in healthcare, Bioiberica actively seeks new strategic partnerships to kickstart exciting developments in the following areas:
- Glycosaminoglycans
- Proteins and bioactive peptides of non-recombinant origin
- Complex lipids
- Other high-value biological substances
Let’s activate to innovate!
[i] Bruyère O, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 Dec;44(3):253-63.
[ii] Rillo O, et al. PANLAR Consensus Recommendations for the Management in Osteoarthritis of Hand, Hip, and Knee. J Clin Rheumatol. 2016 Oct;22(7):345-54.
[iii] Ogata T, et al. Effects of glucosamine in patients with osteoarthritis of the knee: a systematic review and meta-analysis Clin Rheumatol. 2018 Sep;37(9):2479-2487.